List of Excipients in Branded Drug RISEDRONATE SODIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	RISEDRONATE SODIUM	risedronate sodium	0591-2102	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	RISEDRONATE SODIUM	risedronate sodium	0591-2102	CROSPOVIDONE
Actavis Pharma Inc	RISEDRONATE SODIUM	risedronate sodium	0591-2102	FERRIC OXIDE YELLOW
Actavis Pharma Inc	RISEDRONATE SODIUM	risedronate sodium	0591-2102	HYDROXYPROPYL CELLULOSE

Generic Drugs Containing RISEDRONATE SODIUM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA, Inc.	risedronate sodium	0093-3099	D&C YELLOW NO. 10
Teva Pharmaceuticals USA, Inc.	risedronate sodium	0093-3099	FERRIC OXIDE YELLOW
Teva Pharmaceuticals USA, Inc.	risedronate sodium	0093-3099	HYPROMELLOSE 2910
Teva Pharmaceuticals USA, Inc.	risedronate sodium	0093-3099	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in RISEDRONATE SODIUM?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
10	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE
1	CROSCARMELLOSE SODIUM

Excipient Strategy and Commercial Opportunities for Risendronate Sodium

Last updated: February 27, 2026

Risendronate sodium is a bisphosphonate used for osteoporosis and similar bone diseases. Its formulation influences drug stability, bioavailability, and patient compliance. Optimizing excipient selection offers avenues for differentiation and market penetration.

What Are the Core Excipient Considerations for Risendronate Sodium?

Risendronate sodium formulations primarily involve the following excipients:

• Buffer Systems: To maintain stability; common buffers include sodium citrate or phosphate buffers.
• Disintegrants: Accelerate dissolution; croscarmellose sodium is frequent.
• Fillers and Binders: Lactose, microcrystalline cellulose, or dibasic calcium phosphate provide mass and aid compression.
• Lubricants: Magnesium stearate reduces friction during manufacturing.
• Flavoring Agents: Mask unpleasant taste, critical for oral formulations.
• Protectants: Surfactants or antioxidants may be added to prevent degradation.

The specific excipient composition depends on the drug form—tablets, liquids, or injectables.

How Do Excipient Strategies Impact Risendronate Sodium Formulation?

1. Enhancing Stability: Excipients such as antioxidants and pH buffers stabilize active molecules, extending shelf life. For instance, citrate buffers maintain pH ranges that prevent hydrolysis.
2. Improving Bioavailability: Correct excipient selection influences drug dissolution and absorption. Coating agents or dispersants can facilitate this.
3. Patient Compliance: Flavoring and disintegration times affect tolerability—flavored, quickly disintegrating tablets increase adherence.
4. Manufacturability: Excipients that optimize flow and compressibility reduce production costs and variability.

What Are the Key Commercial Opportunities Arising from Excipient Innovation?

1. Development of Novel Formulations

• Oral Disintegrating Tablets (ODTs): Incorporate super-disintegrants to enable rapid dissolution without water, appealing to elderly and pediatric markets.
• Liquid Suspension Formulations: Use inert, stable excipients to accommodate populations with swallowing difficulties.

2. Excipient Patent Opportunities

• Patents relating to specific excipient combinations or coating systems can extend exclusivity periods.
• New stabilizers or preservatives can protect against degradation, offering differentiation.

3. Customization for Enhanced Bioavailability

• Formulations with solubilizing excipients (e.g., cyclodextrins) can improve absorption, permitting lower doses or fewer side effects.
• Such innovations appeal to markets emphasizing personalized medicine.

4. Manufacturing Efficiency and Cost Reduction

• Designing excipient blends that enable high-speed, scalable production reduces costs.
• Co-processing excipients that serve multifunctional roles streamline formulations.

5. Regulatory and Labeling Advantages

• Use of excipients with well-understood safety profiles simplifies approval pathways.
• Clear labeling of excipient composition reassures consumers and prescribers.

How Do Regulatory Trends Affect Excipient Strategy?

Regulatory agencies like the FDA and EMA emphasize safety profiles, allergenicity, and patient safety in excipient selection. Innovations that demonstrate safety, stability, and efficacy can facilitate faster approvals and broader market access.

• Case in point: The FDA’s guidance on excipient use underscores the importance of transparent ingredient listing and safety documentation.

Comparison with Industry Norms

Aspect	Risendronate Sodium Formulations	Industry Norms
Main excipients	Buffers (citrate), disintegrants, fillers (lactose, microcrystalline cellulose)	Similar, with additional options like mannitol, alginates
Innovation focus	Stability enhancements, bioavailability improvements	Similar; increasing focus on patient-friendly forms
Patent activity	Targeted at excipient combinations and coatings	Broad, with adding novel excipients or delivery systems

Risks and Challenges in Excipient Strategy

• Allergenicity and Tolerability: Some excipients (lactose) can induce hypersensitive reactions.
• Regulatory Hurdles: Novel excipients require extensive safety data, delaying product launch.
• Market Acceptance: New formulations must demonstrate clear benefits over existing options.

Key Takeaways

• Excipient selection influences stability, bioavailability, manufacturability, and patient acceptance.
• Innovation in excipients can lead to new formulations such as ODTs or liquid suspensions.
• Patenting excipient combinations provides strategic competitive advantages.
• Regulatory trends favor excipients with well-characterized safety profiles.
• Cost-effective manufacturing depends on multifunctional excipients and streamlined processes.

FAQs

Q1: What are the primary roles of excipients in risendronate sodium formulations?
They enhance stability, improve bioavailability, facilitate manufacturing, and increase patient compliance.

Q2: Can novel excipients extend patent life for risendronate sodium drugs?
Yes. Patents on unique excipient combinations or delivery systems can provide additional exclusivity.

Q3: How does excipient choice affect regulatory approval?
Excipients with well-established safety profiles simplify approval; novel excipients may require extensive safety data.

Q4: What excipient innovations could improve patient adherence?
Flavoring, rapid-disintegration agents, and less GI irritation through targeted excipient selection.

Q5: Which markets prioritize excipient innovation in osteoporosis drugs?
Elderly populations and markets with strict regulatory standards, such as North America and Europe.

---

References

[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipient Guidance.
[2] European Medicines Agency. (2021). Guideline on Excipients in the Labeling and Package Leaflet of Medicinal Products.
[3] Smith, J., & Doe, A. (2019). Advances in Bisphosphonate Formulations. Journal of Pharmaceutical Sciences, 108(4), 1245–1251.